help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aniszewski, J. P.
Right arrow Articles by Bahn, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aniszewski, J. P.
Right arrow Articles by Bahn, R. S.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 2 776-780
Copyright © 2000 by The Endocrine Society

Original Studies

Relationship between Disease Duration and Predominant Orbital T Cell Subset in Graves’ Ophthalmopathy

Jaroslaw P. Aniszewski, Rosanee W. Valyasevi and Rebecca S. Bahn

Division of Endocrinology, Mayo Clinic/Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Rebecca S. Bahn, M.D., Mayo Clinic, Division of Endocrinology, 200 First Street SW, Rochester, Minnesota 55905. E-mail: bahn.rebecca{at}mayo.edu

We sought to determine whether the predominant orbital T helper (TH) cell subset in orbital T cell clones established from patients with Graves’ ophthalmopathy (GO) might be related to disease duration. A total of 117 clones were established from orbital adipose/connective tissues of 6 GO patients, and cytokine production was measured in 57 CD3+CD4+ clones. TH1-type clones were predominant in cultures from patients with recent onset (<2 yr) Graves’ hyperthyroidism (n = 44; TH1/TH0/TH2 = 57/29/14%) or GO (n = 53 clones; TH1/TH0/TH2 = 47/30/23%). In contrast, TH2-type clones predominated in cultures from patients with more remote onset (>2 yr) hyperthyroidism (n = 13; TH1/TH0/TH2 = 0/31/69%; P < 0.005) or GO (n = 4; TH1/TH0/TH2 = 0/25/75%; P = 0.05). In addition, we established T cell clones from 1 TH1-dominant patient with recent-onset thyroid and eye disease using either IL-2 (12.5 ng/mL) alone or IL-2 plus IL-4 (5 ng/mL) and found no shift toward recovery of TH2-type clones in the latter. In conclusion, although the CD3+CD4+ clones characterized were not necessarily tissue antigen specific, our findings suggest that cell-mediated (TH1-type) immune reactions may predominate in the orbit in early GO, whereas humoral immunity (TH2-type) might play the greater role in later stages of the disease.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
X.-M. Mao, H.-Q. Li, Q. Li, D.-M. Li, X.-J. Xie, G.-P. Yin, P. Zhang, X.-H. Xu, J.-D. Wu, S.-W. Chen, et al.
Prevention of Relapse of Graves' Disease by Treatment with an Intrathyroid Injection of Dexamethasone
J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4984 - 4991.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Antonelli, S. M. Ferrari, P. Fallahi, S. Frascerra, E. Santini, S. S. Franceschini, and E. Ferrannini
Monokine Induced by Interferon {gamma} (IFN{gamma}) (CXCL9) and IFN{gamma} Inducible T-Cell {alpha}-Chemoattractant (CXCL11) Involvement in Graves' Disease and Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-{gamma} Agonists
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1803 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. Borgogni, E. Sarchielli, M. Sottili, V. Santarlasci, L. Cosmi, S. Gelmini, A. Lombardi, G. Cantini, G. Perigli, M. Luconi, et al.
Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells
Endocrinology, July 1, 2008; 149(7): 3626 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
C Crescioli, L Cosmi, E Borgogni, V Santarlasci, S Gelmini, M Sottili, E Sarchielli, B Mazzinghi, M Francalanci, A Pezzatini, et al.
Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes
J. Endocrinol., October 1, 2007; 195(1): 145 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, and P. Romagnani
Role of Chemokines in Endocrine Autoimmune Diseases
Endocr. Rev., August 1, 2007; 28(5): 492 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
Y. Inukai, A. Momobayashi, N. Sugawara, and Y. Aso
Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease
Eur. J. Endocrinol., June 1, 2007; 156(6): 623 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. E. Feldon, C. W. O'Loughlin, D. M. Ray, S. Landskroner-Eiger, K. E. Seweryniak, and R. P. Phipps
Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes
Am. J. Pathol., October 1, 2006; 169(4): 1183 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Chen, S. Tsui, W. E. Boeglin, R. S. Douglas, A. R. Brash, and T. J. Smith
Interleukin-4 Induces 15-Lipoxygenase-1 Expression in Human Orbital Fibroblasts from Patients with Graves Disease: EVIDENCE FOR ANATOMIC SITE-SELECTIVE ACTIONS OF Th2 CYTOKINES
J. Biol. Chem., July 7, 2006; 281(27): 18296 - 18306.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Q. Yu, K. Horak, and D. F. Larson
Role of T Lymphocytes in Hypertension-Induced Cardiac Extracellular Matrix Remodeling
Hypertension, July 1, 2006; 48(1): 98 - 104.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Antonelli, M. Rotondi, S. M. Ferrari, P. Fallahi, P. Romagnani, S. S. Franceschini, M. Serio, and E. Ferrannini
Interferon-{gamma}-Inducible {alpha}-Chemokine CXCL10 Involvement in Graves' Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-{gamma} Agonists
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 614 - 620.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Han and T. J. Smith
T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-1{beta} in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy
Endocrinology, January 1, 2006; 147(1): 13 - 19.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. E. Feldon, D. J. J. Park, C. W. O'Loughlin, V. T. Nguyen, S. Landskroner-Eiger, D. Chang, T. H. Thatcher, and R. P. Phipps
Autologous T-Lymphocytes Stimulate Proliferation of Orbital Fibroblasts Derived from Patients with Graves' Ophthalmopathy
Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 3913 - 3921.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Han and T. J. Smith
Induction by IL-1{beta} of Tissue Inhibitor of Metalloproteinase-1 in Human Orbital Fibroblasts: Modulation of Gene Promoter Activity by IL-4 and IFN-{gamma}
J. Immunol., March 1, 2005; 174(5): 3072 - 3079.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
A K Eckstein, B Quadbeck, S Tews, K Mann, C Kruger, C H Mohr, K-P Steuhl, J Esser, and R K Gieseler
Thyroid associated ophthalmopathy: evidence for CD4+ {gamma}{delta} T cells; de novo differentiation of RFD7+ macrophages, but not of RFD1+ dendritic cells; and loss of {gamma}{delta} and {alpha}{beta} T cell receptor expression
Br J Ophthalmol, June 1, 2004; 88(6): 803 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. S. Prabhakar, R. S. Bahn, and T. J. Smith
Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy
Endocr. Rev., December 1, 2003; 24(6): 802 - 835.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Kumar and R. S. Bahn
Relative Overexpression of Macrophage-Derived Cytokines in Orbital Adipose Tissue from Patients with Graves' Ophthalmopathy
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4246 - 4250.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Bahn
Pathophysiology of Graves' Ophthalmopathy: The Cycle of Disease
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1939 - 1946.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Romagnani, M. Rotondi, E. Lazzeri, L. Lasagni, M. Francalanci, A. Buonamano, S. Milani, P. Vitti, L. Chiovato, M. Tonacchera, et al.
Expression of IP-10/CXCL10 and MIG/CXCL9 in the Thyroid and Increased Levels of IP-10/CXCL10 in the Serum of Patients with Recent-Onset Graves' Disease
Am. J. Pathol., July 1, 2002; 161(1): 195 - 206.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. Pichurin, O. Pichurina, G. D. Chazenbalk, C. Paras, C.-R. Chen, B. Rapoport, and S. M. McLachlan
Immune Deviation Away from Th1 in Interferon-{gamma} Knockout Mice Does Not Enhance TSH Receptor Antibody Production after Naked DNA Vaccination
Endocrinology, April 1, 2002; 143(4): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. M. Wiersinga and M. F. Prummel
Pathogenesis of Graves' Ophthalmopathy--Current Understanding
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 501 - 503.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society